TMCnet News
Artelo Biosciences to Participate in BIO Digital and The Investor Summit ConferencesLA JOLLA, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system and related pathways, announced today that it will be participating in two upcoming virtual conferences. Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be speaking on a panel entitled, “Disruptive Thinking: What’s Next for Pain,” at BIO Digital being hosted June 8th-12th, which is available to registered participants in the BIO International Convention. Mr. Gorgas will be discussing new therapeutic approaches in development to treat pain based upon modulation of the endocannabinoid system. Panel speakers will include Rebecca Baker, PhD, Director of Helping to End Addiction Long-term (HEAL) Initiative at the National Institutes of Health and Kimberly Brandt, Principal Deputy Administrator for Policy & Operations at the Centers for Medicaid & Medicare Services. The panel will be moderated by Michael Higgins, Managing Director of Biopharmaceuticals Equity Research at Ladenburg Thalmann & Co. Inc. Additionally, Mr. Gorgas is scheduled to present at the 2020 Virtual Summer Summit on Tuesday, June 9th at 1:35 p.m. Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here, and available for replay on the Company’s website here. One-on-one meetings will be held throughout the conference via video conference calls. About BIO Digital About The Investor Summit About Artelo Biosciences Investor Relations Contact: |